Focused On-demand Library for WD repeat-containing protein 26

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9H7D7

UPID:
WDR26_HUMAN

ALTERNATIVE NAMES:
CUL4- and DDB1-associated WDR protein 2; Myocardial ischemic preconditioning up-regulated protein 2

ALTERNATIVE UPACC:
Q9H7D7; A0MNN3; Q4G100; Q59EC4; Q5GLZ9; Q86UY4; Q9H3C2

BACKGROUND:
The WD repeat-containing protein 26, with alternative names such as CUL4- and DDB1-associated WDR protein 2, is integral to various cellular processes including cell signal transduction, MAPK signaling, and the canonical Wnt signaling pathway. It serves as a scaffolding protein for PLCB2 in leukocytes and is part of the CTLH E3 ubiquitin-protein ligase complex, affecting transcription factor HBP1's stability. Its role extends to cell growth, migration, and apoptosis resistance through different pathways.

THERAPEUTIC SIGNIFICANCE:
Given its critical functions and link to Skraban-Deardorff syndrome, WD repeat-containing protein 26 represents a promising target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies for managing the syndrome and improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1146 of 8789